A Phase 3 interventional study of Abiraterone acetate and Placebo in Prostate Neoplasms, sponsored by Janssen Research & Development, LLC. Completed at 11 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-18.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 16th largest by enrollment, is one of 7 that started in 2012, is one of 11 in phase 3, and was the 24th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 18th largest by enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2012, is one of 15 in phase 3, and was the 29th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate when co-administered with prednisone in Asian patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed docetaxel-based chemotherapy.
This is a randomized (the treatment group is assigned by chance), double-blind (neither physician nor patient knows the treatment that the patient receives) placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study with a randomization allocation ratio of 2:1 between the abiraterone acetate group (abiraterone acetate plus prednisone) and the placebo group (placebo plus prednisone). Approximately 200 (133 in the abiraterone acetate group and 67 in the placebo group) medically or surgically castrated male patients with mCRPC who have failed docetaxel-based chemotherapy will be enrolled in this study for up to 27 months. The study protocol includes the following phases: screening (within 28 days prior to randomization on Cycle 1 Day 1), double-blind treatment (28-day cycles until protocol-defined disease progression or unacceptable toxicity), and survival follow-up (up to Month 60). During the follow-up phase, patients with disease progression will be provided open-label (identity of assigned study drug will be known) extension treatment with abiraterone acetate. In the event of a positive study result at the time of the final analysis, participants in the placebo group who have not shown progressive disease in the double-blind treatment Phase of the study will be enrolled in an open-label extension treatment with abiraterone acetate treatment based on the participant's choice and treating physician's endorsement if they meet the criteria for subsequent abiraterone acetate. Abiraterone acetate 1000 mg tablets or placebo will be taken orally (by mouth) once daily plus prednisone 5 mg tablet orally twice daily. Efficacy and safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abiraterone acetate · Drug: Prednisone
Drug: Placebo · Drug: Prednisone
Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Placebo (4 tablets) taken orally once daily
Prednisone 5 mg tablet taken orally twice daily
DB Phase: Time to Prostate-Specific Antigen Progression (PSA)
Time to PSA progression was defined as time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the Prostate Specific Antigen Working Group (PSAWG) criteria. PSAWG criteria- Decline from baseline and reach response criteria: greater than or equal to (\>=) 50 percent (%) increase over the nadir and the increase in the absolute-value by at least 5 nanogram per milliliter (ng/mL) (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.
Time frame: Up to 1.8 years
DB Phase: Overall Survival
Overall survival was defined as the time interval from the date of randomization to the date of death from any cause.
Time frame: From randomization to the date of death due to any cause (up to approximately 3.8 years)
DB Phase: Percentage of Participants Who Achieved PSA Response
Percentage of participants who achieved PSA response (defined as \>= 50% PSA decline from baseline) according to PSAWG criteria were reported. PSAWG criteria- Decline from baseline and reach response criteria: \>= 50% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.
Time frame: Approximately up to 3.8 years
DB Phase: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Time frame: Approximately up to 3.8 years
DB Phase: Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire: Total Scores at the End of Treatment
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS) (Range 1-156, higher scores better). The FACT-General (FACT-G) is a 28 item Quality of Life (QOL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional (0-24) Well-being. The total range was between 1-108, higher scores better. Functional Assessment of Cancer Therapy-Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Cancer subscale scores; a sensitive measure of patient-reported health (Range 1-104, higher scores better). PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better).
Time frame: Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])
DB Phase: Time to Pain Progression
Time to Pain progression calculated as number of days from date of randomization to date of pain progression. Pain progression- worsening of pain due to metastatic bone disease defined as increase of \>=30% in worst pain over past 24 hours on BPI-SF numeric rating scale at 2 consecutive evaluations 4 weeks apart without decrease in analgesic usage score (in 2 corresponding consecutive evaluation in analgesic usage score, if there is missing visit, use existing visit only) or increase in analgesic usage score \>=30% at 2 consecutive evaluations 4 weeks apart. BPI-SF is 11-item questionnaire which includes 4 questions that assess pain intensity and 7 questions that assess impact of pain on daily functions. Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores= greater pain. Analgesic usage was scored on scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain.
Time frame: Approximately up to 3.8 years
DB Phase: Percentage of Participants Experiencing Pain Palliation
Percentage of participants experiencing pain palliation were reported. A participant is responder if experienced \>=30% reduction in Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity score over 24 hours observed at 2 consecutive evaluations 4 weeks apart without any increase in analgesic usage score (best response). Analgesic usage was scored on a scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions. It includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.
Time frame: Approximately up to 3.8 years
DB Phase: Change From Baseline in Brief Fatigue Inventory (BFI) Score at End of Treatment
The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. BFI has nine items. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people, and enjoyment of life. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes." BFI Total Score is the average of the nine items, ranging from 0 (no fatigue) to 10 (high fatigue).
Time frame: Baseline, at End of Treatment (15 and 30 days after the last dose [up to 3.8 years])
A total of 214 participants were enrolled in the study (143 participants in abiraterone acetate group and 71 participants in placebo group).
| Milestone | Placebo + Prednisone (Double-blind [DB]) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) |
|---|---|---|---|---|
| Started | 71 | 143 | 0 | 0 |
| Completed | 0 | 4 | 0 | 0 |
| Not completed | 71 | 139 | 0 | 0 |
| Withdrew: Progressive disease | 50 | 110 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 14 | 0 | 0 |
| Withdrew: Adverse event | 7 | 7 | 0 | 0 |
| Withdrew: Other | 1 | 3 | 0 | 0 |
| Withdrew: Physician decision | 6 | 3 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 0 | 0 |
| Withdrew: Noncompliance with study drug | 0 | 1 | 0 | 0 |
| Milestone | Placebo + Prednisone (Double-blind [DB]) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) |
|---|---|---|---|---|
| Started | 0 | 0 | 49 | 80 |
| Completed | 0 | 0 | 9 | 10 |
| Not completed | 0 | 0 | 40 | 70 |
| Withdrew: Progressive disease | 0 | 0 | 13 | 22 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 16 |
| Withdrew: Adverse event | 0 | 0 | 11 | 16 |
| Withdrew: Other | 0 | 0 | 4 | 7 |
| Withdrew: Physician decision | 0 | 0 | 4 | 1 |
| Withdrew: Death | 0 | 0 | 2 | 7 |
| Withdrew: Noncompliance with study drug | 0 | 0 | 0 | 1 |
Time to PSA progression was defined as time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the Prostate Specific Antigen Working Group (PSAWG) criteria. PSAWG criteria- Decline from baseline and reach response criteria: greater than or equal to (\>=) 50 percent (%) increase over the nadir and the increase in the absolute-value by at least 5 nanogram per milliliter (ng/mL) (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.
| Days | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| DB Phase: Time to Prostate-Specific Antigen Progression (PSA) | 84.00 (31.00 to 113.00) | 169.00 (141.00 to 197.00) |
Overall survival was defined as the time interval from the date of randomization to the date of death from any cause.
| Days | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| DB Phase: Overall Survival | 561.00 (352.00 to 787.00) | 579.00 (504.00 to 731.00) |
Percentage of participants who achieved PSA response (defined as \>= 50% PSA decline from baseline) according to PSAWG criteria were reported. PSAWG criteria- Decline from baseline and reach response criteria: \>= 50% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL (or back to the baseline), which is confirmed by a second value 4 or more weeks later; Decline from baseline but not reach response criteria: \>=25% increase over the nadir and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later; and No decline from baseline: \>=25% increase over the baseline and the increase in the absolute-value by at least 5 ng/mL, which is confirmed by a second value 4 or more weeks later.
| Percentage of Participants | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| DB Phase: Percentage of Participants Who Achieved PSA Response | 18.3 | 54.5 |
ORR was defined as the percentage of participants with measurable disease at baseline achieving a complete response (CR) or partial response (PR) according to modified response evaluation criteria in solid tumors (RECIST) criteria. RECIST criteria for CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
| Percentage of Participants | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| DB Phase: Objective Response Rate (ORR) | 4.2 | 17.5 |
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT- General + the Prostate Cancer Subscale (PCS) (Range 1-156, higher scores better). The FACT-General (FACT-G) is a 28 item Quality of Life (QOL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional (0-24) Well-being. The total range was between 1-108, higher scores better. Functional Assessment of Cancer Therapy-Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Cancer subscale scores; a sensitive measure of patient-reported health (Range 1-104, higher scores better). PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better).
| Units on a scale | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Total Score | -19.9 ± 22.07 | -16.1 ± 22.74 |
| Physical Well-being | -6.7 ± 6.52 | -4.9 ± 6.85 |
| Functional Well-being | -5.1 ± 6.60 | -2.7 ± 7.31 |
| Emotional Well-being | -2.1 ± 4.48 | -2.4 ± 4.87 |
| Social Well-being | -0.8 ± 3.82 | -1.2 ± 6.55 |
| FACT-G Total Score | -14.6 ± 16.25 | -11.2 ± 17.19 |
| Prostate Cancer Subscale (PCS) | -5.3 ± 7.99 | -4.9 ± 7.70 |
| Treatment Outcome Index (FACT-TOI) | -17.1 ± 17.76 | -12.5 ± 17.52 |
Time to Pain progression calculated as number of days from date of randomization to date of pain progression. Pain progression- worsening of pain due to metastatic bone disease defined as increase of \>=30% in worst pain over past 24 hours on BPI-SF numeric rating scale at 2 consecutive evaluations 4 weeks apart without decrease in analgesic usage score (in 2 corresponding consecutive evaluation in analgesic usage score, if there is missing visit, use existing visit only) or increase in analgesic usage score \>=30% at 2 consecutive evaluations 4 weeks apart. BPI-SF is 11-item questionnaire which includes 4 questions that assess pain intensity and 7 questions that assess impact of pain on daily functions. Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores= greater pain. Analgesic usage was scored on scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain.
| Days | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| DB Phase: Time to Pain Progression | 169.00 (85.00 to 253.00) | 505.00 (365.00 to NA) |
Percentage of participants experiencing pain palliation were reported. A participant is responder if experienced \>=30% reduction in Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity score over 24 hours observed at 2 consecutive evaluations 4 weeks apart without any increase in analgesic usage score (best response). Analgesic usage was scored on a scale of 0 to 3 where 0=no analgesic, 1=non-opioid analgesics, 2=opioids for moderate pain and 3=opioids for severe pain. BPI-SF is 11-item self-reported questionnaire designed to assess severity and impact of pain on daily functions. It includes 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Total score (average of individual questions) ranges from 0=No pain to 10=Pain as bad as you can imagine; Higher scores indicate greater pain.
| Percentage of Participants | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| DB Phase: Percentage of Participants Experiencing Pain Palliation | 31.8 | 54.5 |
The Brief Fatigue Inventory (BFI) is a brief participant-reported questionnaire that measures the severity of fatigue based on the worst fatigue experienced during the past 24-hours. BFI has nine items. Three items ask patients to rate the severity of their fatigue at its "worst," "usual," and "now" during normal waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as you can imagine." Six items assess the amount that fatigue has interfered with different aspects of the patient's life during the past 24 hours. The interference items include general activity, mood, walking ability, normal work (includes both work outside the home and housework), relations with other people, and enjoyment of life. The interference items are measured on a 0-10 scale, with 0 being "does not interfere" and 10 being "completely interferes." BFI Total Score is the average of the nine items, ranging from 0 (no fatigue) to 10 (high fatigue).
| Units on a scale | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) |
|---|---|---|
| Fatigue Now | 2.4 ± 3.59 | 1.7 ± 3.34 |
| Usual Fatigue | 2.4 ± 3.53 | 1.5 ± 3.18 |
| Worst Fatigue | 2.6 ± 3.73 | 1.6 ± 3.49 |
| General Activity | 2.3 ± 3.65 | 1.7 ± 3.38 |
| Mood | 2.7 ± 3.39 | 1.8 ± 3.40 |
| Walking Ability | 2.4 ± 3.28 | 1.8 ± 3.50 |
| Normal Work | 2.2 ± 3.84 | 2.0 ± 3.71 |
| Relations with Other People | 2.0 ± 3.08 | 1.6 ± 3.25 |
| Enjoyment of Life | 2.5 ± 3.33 | 1.9 ± 3.64 |
Collected over Approximately up to 3.8 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Prednisone (Double-blind) | — | 20/71 (28.2%) | 62/71 (87.3%) |
| Abiraterone Acetate + Prednisone (Double-blind) | — | 33/143 (23.1%) | 134/143 (93.7%) |
| Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | — | 25/49 (51%) | 35/49 (71.4%) |
| AA + Prednisone to AA + Prednisone (Open-label) | — | 41/80 (51.3%) | 54/80 (67.5%) |
| Event | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) |
|---|---|---|---|---|
| Disease progressionGeneral disorders | 5/71 | 6/143 | 8/49 | 17/80 |
| AnaemiaBlood and lymphatic system disorders | 0/71 | 3/143 | 2/49 | 5/80 |
| Lung infectionInfections and infestations | 0/71 | 2/143 | 3/49 | 4/80 |
| PyrexiaGeneral disorders | 1/71 | 1/143 | 1/49 | 4/80 |
| Multi-organ failureGeneral disorders | 0/71 | 1/143 | 2/49 | 3/80 |
| Bone painMusculoskeletal and connective tissue disorders | 2/71 | 3/143 | 2/49 | 3/80 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/71 | 0/143 | 0/49 | 2/80 |
| DeathGeneral disorders | 0/71 | 0/143 | 0/49 | 2/80 |
| Platelet count decreasedInvestigations | 0/71 | 0/143 | 0/49 | 2/80 |
| FatigueGeneral disorders | 0/71 | 0/143 | 1/49 | 0/80 |
| Event | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Placebo + Prednisone (DB) to AA + Prednisone (Open-label) | AA + Prednisone to AA + Prednisone (Open-label) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 16/71 | 38/143 | 13/49 | 29/80 |
| HypokalaemiaMetabolism and nutrition disorders | 10/71 | 39/143 | 8/49 | 14/80 |
| Bone painMusculoskeletal and connective tissue disorders | 15/71 | 36/143 | 6/49 | 4/80 |
| Aspartate aminotransferase increasedInvestigations | 12/71 | 29/143 | 7/49 | 9/80 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 11/71 | 17/143 | 2/49 | 1/80 |
| HypertensionVascular disorders | 9/71 | 22/143 | 3/49 | 4/80 |
| Back painMusculoskeletal and connective tissue disorders | 9/71 | 20/143 | 5/49 | 4/80 |
| Alanine aminotransferase increasedInvestigations | 9/71 | 20/143 | 6/49 | 5/80 |
| Decreased appetiteMetabolism and nutrition disorders | 9/71 | 3/143 | 4/49 | 2/80 |
| Oedema peripheralGeneral disorders | 9/71 | 10/143 | 2/49 | 5/80 |
| Age, Continuous(years) | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Total |
|---|---|---|---|
| Mean | 67.7 ± 7.75 | 68.2 ± 8.3 | 68 ± 8.11 |
| Sex: Female, Male(Participants) | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 71 | 143 | 214 |
| Race/Ethnicity, Customized(Participants) | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Total |
|---|---|---|---|
| Asian | 71 | 143 | 214 |
| Region of Enrollment(Participants) | Placebo + Prednisone (Double-blind) | Abiraterone Acetate + Prednisone (Double-blind) | Total |
|---|---|---|---|
| China | 71 | 143 | 214 |
Ran from Aug 2012 to primary completion in Jun 2014, 22 months.
Results were first posted in Jul 2019, 5 years after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 22 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate
Janssen Research & Development, LLC →